Overview
The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers
Status:
Completed
Completed
Trial end date:
2016-02-01
2016-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to determine whether or not Recombinant DNA-based hyaluronidase (RDNAH/Hylenex recombinant), is safe and effective for dissolving hyaluronic acid (HA) dermal fillers.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Steve Yoelin M.D. Medical Associates, Inc.Treatments:
Hyaluronic AcidCriteria
Inclusion Criteria:- Male or female 18 years of age or older
- Able to speak/write in the English language
- Negative Pregnancy Test on Day 1
- Proposed injection site must be free of any active inflammation
Exclusion Criteria:
- Pregnant or breast feeding
- History of keloid formation
- History of allergic reaction to hyaluronic acid dermal fillers, hyaluronidase, or any
ingredients of the aforementioned products
- Active, uncontrolled inflammatory condition of any type
- History of allergic reaction to lidocaine